Clinicopathological analysis of HOXD4 expression in diffuse gliomas and its correlation with <i>IDH</i> mutations and 1p/19q co-deletion

Xinwei Zhao, Yunbo Zhan, Jian-Ji Bao, Jinqiao Zhou, Fengjiang Zhang, Bin Yu, Yahui Bai, Yanmin Wang, Xianzhi Liu

Oncotarget · 2017 · 10 citations · 15 references

DOIFull text

Open access

Concepts

Abstract

// Xin-Wei Zhao 1, * , Yun-Bo Zhan 1, * , Jian-Ji Bao 1 , Jin-Qiao Zhou 1 , Feng-Jiang Zhang 1 , Yu Bin 1 , Ya-Hui Bai 1 , Yan-Min Wang 1 , Zhen-Yu Zhang 1 and Xian-Zhi Liu 1 1 Department of Neurosurgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450001, China * These authors have contributed equally to this work Correspondence to: Zhen-Yu Zhang, email: neurozzy@foxmail.com Xian-Zhi Liu, email: xzliu06@126.com Keywords: gliomas; HOXD4; immunohistochemistry; TCGA; prognosis Received: November 03, 2017&emsp;&emsp;&emsp;&emsp; Accepted: December 05, 2017&emsp;&emsp;&emsp;&emsp; Published: December 18, 2017 ABSTRACT Backgrounds: HOX (homologous box) is known as the dominant gene of vertebrate growth and cell differentiation. Abnormal expression of HOX gene in various tumors has attracted the attention of scholars. As a component of HOX clusters, HOXD4 plays a controversial role in the tumorigenesis of central nervous system. Results : The data demonstrated that and the results demonstrated that HOXD4 was overexpressed in glioma tissues compared to that of normal brain tissues. patients with high HOXD4 expression had a significant shorter survival than those with low HOXD4 expression in total glioma cohort ( p &lt;0.001), WHO Grade II cohort ( p =0.003) and Grade III cohort ( p &lt;0.001), but not in Grade IV cohort when OS (overall survival) was analyzed ( p =0.216). The findings were confirmed by the large-scale omics data analysis including lower-grade glioma (LGG) and glioblastoma multiforme (GBM) in TCGA (the cancer genome atlas) and CGGA (Chinese glioma genome atlas). Moreover, it was revealed that the expression of HOXD4 have a significant impact on the OS of Grade IV glioma with IDH wild-type and 1p/19q intact according to TCGA data. Methods : Clinicopathological analysis of HOXD4 expression in 453 glioma patients was performed in the current study. Expression of HOXD4 was evaluated by qPCR and immunohistochemical (IHC) staining. Univariate and multivariate analysis were conducted to investigate the prognostic role of HOXD4 in glioma patients. Conclusions : Expression of HOXD4 was closely related to the clinical outcomes of patients with gliomas, and HOXD4 may be a potential prognostic biomarker of gliomas.

References

15